DrugBiological
Epcoritamab clinical trials
Also written GEN3013 and Epkinly.
- studies test it
- 50
- open now
- 36
- in phase 3
- 6
- first study started
- 2018
Keep track of what changes. Save the epcoritamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2025 (16); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 10 |
| 2025 | 16 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 37
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 40
Genmab (10) · City of Hope Medical Center (4) · The Lymphoma Academic Research Organisation (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · M.D. Anderson Cancer Center (2) · Reid Merryman, MD (2) · Memorial Sloan Kettering Cancer Center (2) · AIDS Malignancy Consortium (1)
Often tested with
Tested in the same studies.
Lenalidomide (9) · Rituximab (7) · Oxaliplatin (3) · Gemcitabine (3) · Ibrutinib (3) · Venetoclax (3) · Loncastuximab tesirine (2) · Tafasitamab (2)
Studies
Open first, then newest update. How each study uses epcoritamab is read from its arms, and is right about nine times in ten.
Testing it · 50
- Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Not yet recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT07882173Written as epcoritamab
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT07097363Written as Epcoritamab
- Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK StudyNot yet recruitingPhase 2AIDS Malignancy ConsortiumNCT07662928Written as Epcoritamab
- Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 2University of MiamiNCT06919939Written as Epcoritamab
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)RecruitingPhase 2Izidore Lossos, MDNCT06796998Written as Epcoritamab
- Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLRecruitingPhase 1/2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT05791409Written as Epcoritamab
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingPhase 2Carrie Ho, MDNCT07588698Written as Epcoritamab
- Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07126236Written as Epcoritamab
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingPhase 2Reid Merryman, MDNCT06563596Written as Epcoritamab
- Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06045247Written as Epcoritamab
- Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersRecruitingPhase 1Timothy VoorheesNCT06672705Written as Epcoritamab
- Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07783594Written as Epcoritamab
- Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKINot yet recruitingPhase 2University of California, IrvineNCT07819214Written as Epcoritamab
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07814001Written as Epcoritamab
- Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT07365306Written as Epcoritamab
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Yazeed SawalhaNCT06536049Written as Epcoritamab
- Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07738887Written as Epcoritamab
- Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingPhase 2Universität MünsterNCT07197307Written as Loncastuximab Tesirine and Epcoritamab
- Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit PatientsNot yet recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT07714421Written as Epcoritamab
- A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07082868Written as Epcoritamab
See all 50 studies that test epcoritamab →
Given in every arm · 10 — epcoritamab is usual care beside what is tested
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRecruitingPhase 1/2Bristol-Myers SquibbNCT06090539Written as Epcoritamab
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Epcoritamab
- Outpatient Epcoritamab in Large B-cell LymphomaRecruitingPhase 2Massachusetts General HospitalNCT06811272Written as Epcoritamab
- Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell LymphomaRecruitingPhase 2Dipenkumar ModiNCT05852717Written as Epcoritamab
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedPhase 2GenmabNCT05660967Written as Epcoritamab
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruitingPhase 1/2GenmabNCT04623541Written as Epcoritamab
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingPhase 1/2GenmabNCT04663347Written as Epcoritamab
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1/2GenmabNCT05201248Written as Epcoritamab
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as Epcoritamab
- First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin LymphomasTerminatedPhase 1/2GenmabNCT04358458Written as Epcoritamab
Codes
What other systems call epcoritamab · ClinicalTrials.gg INT002168
- MeSH (NLM) C000731938epcoritamabOne source NLM
- UNII (FDA) D6OMY2L0WAEPCORITAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q119025940epcoritamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C163022EpcoritamabOne source FDA
- DrugBank DB16672One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731938 | epcoritamab | One source NLM |
| UNII (FDA) | D6OMY2L0WA | EPCORITAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q119025940 | epcoritamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C163022 | Epcoritamab | One source FDA |
| DrugBank | DB16672 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.